Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Immune Assays Team, Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team, United States Government (USG)/CoVPN Biostatistics Team

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured two weeks post-dose two are assessed as correlates of risk and as correlates of protection against COVID-19. Analyses are conducted in the U.S. cohort of baseline SARS-CoV-2 negative per-protocol participants using a case-cohort design that measures the markers from all 12 vaccine recipient breakthrough COVID-19 cases starting 7 days post antibody measurement and from 639 vaccine recipient non-cases. All markers are inversely associated with COVID-19 risk and directly associated with vaccine efficacy. In vaccine recipients with nAb ID50 titers of 50, 100, and 7230 international units (IU50)/ml, vaccine efficacy estimates are 75.7% (49.8%, 93.2%), 81.7% (66.3%, 93.2%), and 96.8% (88.3%, 99.3%). The results support potential cross-vaccine platform applications of these markers for guiding decisions about vaccine approval and use.

Original languageEnglish
Article number331
JournalNature Communications
Issue number1
StatePublished - Dec 2023
Externally publishedYes


Dive into the research topics of 'Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial'. Together they form a unique fingerprint.

Cite this